Cardiva is divided into EWMA 2025 with two innovation for complex wounds

Barcelona This year hosted the European Wound Association Conference (EWMA 2025A major event that brings together more than 6500 specialists in this sector. In this context, Cardiva It takes a firm step in its position inside Chronic wounds With a display Innovative treatment solutions: Debrechem, from Debx Medical, and Reoxcare, developed by Histocell. Both technicians, despite their difference in their work mechanism, were perceived as remedy with a costume approach in the integrated approach to complex wounds.

“This is the first time that Cardiva is located in EWA and the experience is very positive and surprising.”He refers to Albert Sanjoin, Director of Cardiovascular and Vascular Surgery of the company. “We receive a lot of attention and the size of Congress, with only 2,500 participants from Spain, it allows The first promising promising communication “.

Debrichem: A model in preparing a wound bed

Both analysts, Debrichem is placed as a sabotage tool. “It is an innovative treatment for the advanced preparation for the wound bed,” explains Mark Klabra, the global sales manager for Medical Debx. Immediate effect: “It works on preserved tissues, infection and biological membrane in just 60 seconds, allowing the healing process to accelerate significantly.”

The clinical effect is great, but also its effect on loading of well -being. According to CLAPERA, “We can avoid procedures such as surgical excavation, Which can cost more than 4000 euros, and reduce hospital stays. “ In primary care, the simplicity of treatment allows “to reduce the number of visits and use multiple products.”

However, the biggest challenge of Debrichem lies in its merging in the current clinical practice. “Like any revolutionary innovation, you need to find its place inside the protocols that are used to working differently,” says CLAPERA. However, the capabilities are clear: “There is no other product that guarantees 100 % effectiveness against the vital membranes in one application.”

Reoxcare: Eliminate oxidative stress, a basic step in recovery

To complete Debrichem in this double approach, Reoxcare treats one of the most related barriers in recovery: oxidative stress. “We are the only company that has a specific antioxidant technology,” BEGOñA Castro, Histocell Scientific Director. “This grandmother allows the stimulation of the wound by eliminating this barrier, which makes a difference in treatment.”

Reoxcare is witnessing a gradual growth on the market, especially in Spain, where Histocell begins integration as a technological reference. “Every country has organizational peculiarities and its repayment, which makes the product to penetrate gradually, but it is fixed.”Castro explains. “In EWMA, playing at home inflates our vision at the European level, allowing our antioxidant strategy to reach angles, otherwise, it will be difficult to reach.”

A treatment alliance with an integrated vision

Cardiva is not betting on innovative products, but also a therapeutic integration strategy. “They are completely different producers, working in different stages of the wound, but we believe they are very visible,” says Sanjuan. “One removes the problem of vital membranes quickly and in one application, and allows the injury to the granulation stage, where Reoxcare works effectively to unify healing.”

Adherence to this line responds to the vascular surgery department of strategic vision. “By contacting the blood vessels and their experience in complex wounds, such as those associated with the patient’s feet, “We have seen an opportunity to re -put these solutions and that patients benefit directly.”